Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

People In The News: EFPIA Seeks New Leader, Medicines Australia Finds One

Executive Summary

EFPIA's Richard Bergström is moving on; Medicines Australia brings in UK-based lobbyist Milton Catelin as its CEO; Friends of Cancer Research promotes Jeff Allen to CEO, plus more biopharma personnel changes.

You may also be interested in...



O’Neill Optimistic Global AMR Review Won’t Lose Steam

Jim O'Neill says he spends sleepless nights worrying whether his Review of Antimicrobial Resistance (AMR) will run out of steam once completed in two months' time - but he's encouraged by growing evidence world leaders and the pharma industry are seriously embracing the theme and will soon make lasting commitments to effectively combat antibiotic resistance, including in Asia.

Medicines Australia CEO Resigns After "Challenging" Year

Tim James has resigned as CEO of the pharmaceutical industry body Medicines Australia, effective from January 20161. The search for a successor will begin next year.

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS119050

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel